Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Earnings Calls In Brief

This article was originally published in The Gray Sheet

Executive Summary

HeartWare increases international sales

You may also be interested in...



News In Brief

Thoratec divests ITC division

Research In Brief

Vertebroplasty benefit: In patients with acute osteoporotic vertebral compression fractures and persistent pain, percutaneous vertebroplasty provides immediate pain relief that is sustained for at least a year and is significantly greater than optimum pain treatment on a visual analog scale (VAS), according to a study posted online Aug. 9 by the Lancet. Data from the VERTOS II trial show the difference in mean VAS score reduction between vertebroplasty and conservative therapy was 2.6 at one month and 2.0 at one year. The results contrast with findings from two studies published in the New England Journal of Medicine last year that concluded there was no difference between vertebroplasty and sham treatment in spine fracture patients (1"The Gray Sheet" Aug. 10, 2009). Unlike VERTOS II, those trials included subacute fractures up to a year old, Caroline Klazen, St. Elisabeth Ziekenhuis, Netherlands, et al., point out. VERTOS II began therapy five-six weeks after the onset of pain, which suggests the procedure, when done earlier, is "more effective for pain relief than is treatment up to a year after onset.

Korea Regulatory Streamlining Plans Eye Innovation, Commercialization Support

South Korea's drug ministry, together with consumer and business groups, announces a raft of major regulatory innovation tasks it aims to achieve over the next few years, a major goal being to speed up patient access to innovation.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT029565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel